A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | MicrobiomeTrials← Back to trialsNCT04225117
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2020-03-10Est. Completion: 2025-02-25
Enrollment target: 329 participants Locations- Arizona Oncology, Tucson, Arizona, United States
- University of California - San Francisco, San Francisco, California, United States
- University of Colorado, Aurora, Colorado, United States
- Florida Cancer Specialists, Fort Myers, Florida, United States
- Florida Cancer Specialists, Tallahassee, Florida, United States
- Florida Cancer Specialists, West Palm Beach, Florida, United States
- Piedmont Hospital, Atlanta, Georgia, United States
- Northside Hospital, Atlanta, Georgia, United States
- Northwestern University Medical Center, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Indiana University Cancer Center, Indianapolis, Indiana, United States
- University of Kansas, Fairway, Kansas, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Other microbiome trials you might be interested in
Advanced Solid Tumor
The aim of this first-in-human (FIH) open-label, multi-site study is to evaluate safety, tolerability, pharmacokinetics …
Adelaide, AustraliaEst. completion Nov 2027
Locally Advanced Gastrointestinal Stromal TumorMetastatic Gastrointestinal Stromal TumorRecurrent Gastrointestinal Stromal TumorRefractory Malignant Gastrointestinal Stromal TumorUnresectable Malignant Gastrointestinal Stromal Tumor
Nebraska Methodist Hospital, Omaha, Nebraska, United StatesComprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United StatesRutgers Cancer Institute, New Brunswick, New Jersey, United StatesNew York University Langone Health, New York, New York, United StatesMemorial Sloan Kettering Cancer Center, New York, New York, United StatesCleveland Clinic, Cleveland, Ohio, United StatesOhio State University, Columbus, Ohio, United StatesGettysburg Cancer Center, Gettysburg, Pennsylvania, United StatesSarah Cannon Research Institute, Nashville, Tennessee, United StatesMary Crowley Research Center, Dallas, Texas, United StatesUniversity of Texas, Houston, Texas, United StatesSeattle Cancer Care Alliance, Seattle, Washington, United StatesWisconsin Carbone Cancer Center, Madison, Wisconsin, United StatesSite CA15003, Ottawa, Ontario, CanadaSite JP81004, Nagoya, Aichi-ken, JapanSite JP81001, Kashiwa, Chiba, JapanSite JP81005, Chuo-ku, Osaka, JapanSite JP81007, Ōsaka-sayama, Osaka, JapanSite JP81011, Kitaadachi-Gun, Saitama, JapanSite JP81006, Nakatogari, Shizuoka, JapanSite JP81003, Chūō, Tokyo, JapanSite JP81002, Koto, Tokyo, JapanSite JP81010, Okayama, JapanThis phase II trial tests the effect of autologous tumor infiltrating lymphocytes (TILs) in combination with interleukin…
Columbus, United StatesEst. completion Dec 31, 2027